✦ LIBER ✦

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia

✍ Scribed by Mesa, R A; Camoriano, J K; Geyer, S M; Wu, W; Kaufmann, S H; Rivera, C E; Erlichman, C; Wright, J; Pardanani, A; Lasho, T

Book ID: 110058326
Publisher: Nature Publishing Group
Year: 2007
Tongue: English
Weight: 139 KB
Volume: 21
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2404816

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of 5-azacitidine for pa

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis

✍ Tong, W; Kantarjian, H; Thomas, D; Ravandi, F; Kornblau, S; Manshouri, T; Cortes 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 132 KB

Primary myelofibrosis (PMF), post polycy

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)

✍ Ruben A. Mesa; Srdan Verstovsek; Francisco Cervantes; Giovanni Barosi; John T. R 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 113 KB

The International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) is comprised of hematologists, hematopathologists, and laboratory scientists and its main goal is to provide a forum for scientific exchange and collaboration. During its first general meeting in April 2006, the IWG-M

Proposed criteria for the diagnosis of p

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

✍ Barosi, G; Mesa, R A; Thiele, J; Cervantes, F; Campbell, P J; Verstovsek, S; Dup 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 81 KB

IDH1 and IDH2 mutation studies in 1473 p

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

✍ Tefferi, A; Lasho, T L; Abdel-Wahab, O; Guglielmelli, P; Patel, J; Caramazza, D; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 460 KB

A phase II trial of pegylated interferon

A phase II trial of pegylated interferon α-2b therapy for polycythemia vera and essential thrombocythemia : Feasibility, clinical and biologic effects, and impact on quality of life

✍ Jan Samuelsson; Hans Hasselbalch; Oystein Bruserud; Snezana Temerinac; Yvonne Br 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

A higher JAK2 V617F-mutated clone is obs

A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis

✍ Bellosillo, B; Martínez-Avilés, L; Gimeno, E; Florensa, L; Longarón, R; Navarro, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 93 KB